Cellectar Biosciences Inc.

0.4116-0.0285-6.48%Vol 153.87K1Y Perf -64.22%
Jun 24th, 2022 16:00 DELAYED
BID0.3551 ASK0.4800
Open0.4500 Previous Close0.4401
Pre-Market- After-Market0.43
 - -  0.02 4.98%
Target Price
4.95 
Analyst Rating
Strong Buy 1.00
Potential %
1.10K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
7.59 
Earnings Rating
Buy
Market Cap25.15M 
Earnings Date
8th Aug 2022
Alpha-0.06 Standard Deviation0.18
Beta1.59 

Today's Price Range

0.41160.4600

52W Range

0.33701.32

5 Year PE Ratio Range

-3.10-0.7000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
7.47%
1 Month
5.54%
3 Months
-38.11%
6 Months
-41.20%
1 Year
-64.22%
3 Years
-80.68%
5 Years
-97.54%
10 Years
-99.98%

TickerPriceChg.Chg.%
CLRB0.4116-0.0285-6.48
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.11-0.109.09
Q04 2021-0.10-0.100.00
Q03 2021-0.11-0.109.09
Q02 2021-0.11-0.110.00
Q01 2021-0.09-0.13-44.44
Q04 2020-0.15-0.0753.33
Q03 2020-0.15-0.150.00
Q02 2020-0.30-0.2613.33
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.110.00-
9/2022 QR-0.110.00-
12/2022 FY-0.404.76Positive
12/2023 FY-0.35-2.94Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report-0.11
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume153.87K
Shares Outstanding61.10K
Shares Float60.81M
Trades Count273
Dollar Volume66.75K
Avg. Volume111.77K
Avg. Weekly Volume67.29K
Avg. Monthly Volume117.79K
Avg. Quarterly Volume150.24K

Cellectar Biosciences Inc. (NASDAQ: CLRB) stock closed at 0.4116 per share at the end of the most recent trading day (a -6.48% change compared to the prior day closing price) with a volume of 153.87K shares and market capitalization of 25.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cellectar Biosciences Inc. CEO is James V. Caruso.

The one-year performance of Cellectar Biosciences Inc. stock is -64.22%, while year-to-date (YTD) performance is -38.01%. CLRB stock has a five-year performance of -97.54%. Its 52-week range is between 0.337 and 1.32, which gives CLRB stock a 52-week price range ratio of 7.59%

Cellectar Biosciences Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.93%, a ROC of -74.10% and a ROE of -77.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cellectar Biosciences Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Cellectar Biosciences Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Cellectar Biosciences Inc. is Strong Buy (1), with a target price of $4.95, which is +1 102.62% compared to the current price. The earnings rating for Cellectar Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cellectar Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cellectar Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.34, ATR14 : 0.04, CCI20 : 65.99, Chaikin Money Flow : -0.26, MACD : -0.01, Money Flow Index : 46.77, ROC : 0.02, RSI : 49.65, STOCH (14,3) : 60.65, STOCH RSI : 0.67, UO : 46.57, Williams %R : -39.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cellectar Biosciences Inc. in the last 12-months were: Douglas J. Swirsky (Buy at a value of $26 000), Frederick W. Driscoll (Buy at a value of $20 244)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.

CEO: James V. Caruso

Telephone: +1 608 441-8120

Address: 100 Campus Drive, Florham Park 07932, NJ, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

61%39%

Bearish Bullish

57%43%

News

Stocktwits